Biological Dynamics, Inc.

34 articles about Biological Dynamics, Inc.

• Biological Dynamics Case Report Published in Frontiers in Oncology Demonstrates Advancement in the Detection of Early-Stage Pancreatic Lesions

  5/26/2023

  Biological Dynamics announced the publication of a case report, “Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy,” in Frontiers in Oncology, highlighting the successful detection of early-stage pancreatic ductal adenocarcinoma lesions using its exosome liquid biopsy assay, ExoVitaTM Pancreas.

• Biological Dynamics to Present Data at AACR Highlighting ExoVerita Platform-Enabled Earlier Detection of Pancreatic and Lung Cancers

  4/14/2023

  Biological Dynamics will present data showing how the company’s ExoVerita™ platform can be utilized for early detection of lung and pancreatic cancers at the American Association of Cancer Research annual meeting in Orlando, Fl., April 14-19.

• Biological Dynamics and Oregon Health & Science University Collaborate on Early-Stage Pancreatic Cancer Detection Study

  3/1/2023

  Biological Dynamics, Inc., a company developing and commercializing its exosome-isolation ExoVerita™ platform for early disease diagnostics and other applications, announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University to study its ExoVita™ Pancreas assay.

• Biological Dynamics launches ExoVita™ Pancreas and enrolls patients in ExoLuminate clinical trial

  2/8/2023

  Biological Dynamics, Inc., a company commercializing its exosome-isolation ExoVerita™ platform for early disease surveillance and other applications, today announced completion of the analytical and clinical validation of its lab developed test (LDT), ExoVita™ Pancreas in the company’s CLIA certified and CAP accredited laboratory.

• Biological Dynamics, Perlmutter Cancer Center at NYU Langone Health collaborate on pancreatic cancer research

  1/31/2023

  Biological Dynamics, a company commercializing its exosome-isolation ExoVerita™ platform, announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma.

• Biological Dynamics to deliver showcase presentation at Precision Medicine World Conference

  1/24/2023

  Biological Dynamics’ Medical Director, Harmeet Dhani, MD, MSc to present data demonstrating clinical utility of the ExoVerita™ exosome-isolation platform for detection of early-stage cancers.

• Biological Dynamics Appoints Industry Veteran Peter Wulff as Chief Financial Officer

  1/17/2023

  Biological Dynamics, Inc., a company developing and commercializing its proprietary ExoVerita™ platform for early disease detection and other applications, today announced Peter C. Wulff as Chief Financial Officer effective January 1, 2023.

• Biological Dynamics Files Legal Action Against Co-founders of EXOKĒRYX

  1/4/2023

  Biological Dynamics announced it has filed arbitration against two former employees, Richard Young and Bryan Rice, alleging that they have misappropriated Biological Dynamics’ proprietary technology to benefit their new company, EXOKĒRYX, Inc.

• Biological Dynamics to participate at 2022 PRECEDE Biomarker Summit

  12/7/2022

  Biological Dynamics, a company developing its exosome-isolation ExoVerita™ platform for early disease diagnostics, announced today that its Director of Medical Affairs, Harmeet Dhani, MD, MSc, will speak at the inaugural PRECEDE Early Detection Biomarker Summit in New York. 

• Biological Dynamics announces prospective clinical trial, ExoLuminate™

  12/1/2022

  Biological Dynamics, a company developing its exosome-isolation ExoVerita™ platform for early disease diagnostics, announced today it has received IRB approval and will soon begin to enroll patients in its ExoLuminate™ clinical study to validate its pancreatic ductal adenocarcinoma (PDAC) lab-developed test (LDT).

• Biological Dynamics collaborates on clinical utility studies to examine the impact of its early pancreatic cancer detection assay

  11/22/2022

  Biological Dynamics, an exosome-isolation technology and early disease detection diagnostic company, today announced that it has partnered with both QURE Healthcare and Curta to explore how the company's assay for early detection of pancreatic ductal adenocarcinoma (PDAC) can improve patient outcomes, demonstrate the greatest value to clinicians, and enhance healthcare economics.

• Biological Dynamics, an early detection disease management company, expands leadership

  11/10/2022

  Biological Dynamics, an exosome isolation technology and early disease detection company, announced new executive appointments to fuel its growth.

• Biological Dynamics to Present at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit

  8/3/2022

  Biological Dynamics, Inc. today announced that the company will participate at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.

• Biological Dynamics Selected as Finalist for the 2022 AACC Disruptive Technology Award

  6/14/2022

  Award Recognizes the Company’s Verita ™ Isolation Platform, which Enables Early-Stage Cancer Detection.

• Biological Dynamics to Participate in Key Life Science and Healthcare Meetings

  3/31/2022

  Biological Dynamics, Inc., a biotechnology company focused on detecting diseases at the earliest stages, announced participation in a series of global events to discuss industry trends and challenges, and to preview new early-stage cancer detection data based on the company’s novel Verita™ technology.

• Biological Dynamics Study Demonstrates Detection of Early-Stage Cancers

  3/17/2022

  Biological Dynamics, Inc. announces the publication of its study, Early-Stage Multi-Cancer Detection Using an Extracellular Vesicle Protein-Based Blood Test, published in Nature Communications Medicine.

• 

  BioSpace Movers & Shakers, March 11

  3/11/2022

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers

• Precision Medicine Expert Dr. Paul Billings Rejoins Biological Dynamics, Inc. as Chief Executive Officer and Director

  3/8/2022

  Biological Dynamics, Inc., a novel multiomic test company focused on detecting diseases at their earliest stages, announced the return of Paul Billings, MD, PhD, FACP, FACMGG to the company as Chief Executive Officer and Director.

• FDA Grants Breakthrough Device Designation for Biological Dynamics’ Early-stage Pancreatic Cancer Detection Test

  10/20/2021

  Biological Dynamics, Inc., a multiomics liquid biopsy company focused on detecting cancers at the earliest stages, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its liquid biopsy assay, Exo-PDAC.

• Biological Dynamics to Present at UBS Genomics 2.0 and MedTech Innovations Summit

  8/6/2021

  Biological Dynamics, Inc. will present at the UBS Genomics 2.0 and MedTech Innovations Summit in Laguna Beach, California. The panel discussion takes place on Tuesday, August 10, 2021 at 7:00 p.m. PT.